TCG Crossover Management, LLC — 13F Holdings & Portfolio
CIK 1839948 · latest 13F-HR filed 2026-08-14
TCG Crossover Management, LLC manages $4.16B in 13F-reported U.S. long-equity assets across 54 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (19.24%), TNGX (6.82%), CGON (6.27%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 12 new positions and exited 7; 27 existing positions rose in reported value and 11 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 57.4%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated May 29, 2026.
SUITE 350
PALO ALTO, CA 94301
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| SKALING, CRAIG, DAVID Control | CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER since Feb 2022 | Less than 5% | Individual |
| YU, CHEN, MING Control | MANAGING PARTNER since Oct 2020 | 75% or more | Individual |
Ownership & leadership changes · 1 filing with changes since Nov 18, 2020
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedFELIX, JAIME, MORA · CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Oct 2020
- AddedSKALING, CRAIG, DAVID · CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedFELIX, JAIME, MORA · CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedYU, CHEN, MING · MANAGING PARTNER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ABIVAX SA AMERICAN DEPOSITARY SHARES$78.9M +10.9%
- SPYRE THERAPEUTICS INC$72.9M +76.0%
- TANGO THERAPEUTICS INC$63.6M +28.9%
- IMMUNOVANT INC$61.0M +55.1%
- AVALO THERAPEUTICS INC$44.7M +405.8%
Top Trims
- ADC THERAPEUTICS SA-$30.5M -71.5%
- ENTRADA THERAPEUTICS INC-$21.1M -73.0%
- TYRA BIOSCIENCES INC-$20.7M -16.6%
- ARVINAS HOLDING CO LLC-$19.4M -76.8%
- ALX ONCOLOGY HOLDINGS INC-$14.4M -55.1%
New Positions
- ZAI LAB LTD-ADR$116.6M
- AURA BIOSCIENCES INC$67.7M
- FIRST TRACKS BIOTHERAPEUTICS$58.3M
- EDITAS MEDICINE INC$36.0M
- PHARVARIS BV$34.9M
Exited Positions
- CENTESSA PHARMACEUTICALS PLC$170.3M
- FULCRUM THERAPEUTICS INC$40.3M
- LIQUIDIA TECHNOLOGIES INC$15.2M
- UROGEN PHARMA LTD$7.3M
- STRUCTURE THERAPEUTICS INC$6.8M
TCG Crossover Management, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ABIVAX SA AMERICAN DEPOSITARY SHARES | ABVX | 00370M103 | $800.6M | 19.24% | 6,007,834 | SH |
| 2 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $283.9M | 6.82% | 9,081,201 | SH |
| 3 | CG ONCOLOGY INC | CGON | 156944100 | $260.8M | 6.27% | 3,670,206 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $187.9M | 4.52% | 4,854,436 | SH |
| 5 | IMMUNOVANT INC | IMVT | 45258J102 | $171.8M | 4.13% | 4,457,988 | SH |
| 6 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $168.7M | 4.06% | 1,900,582 | SH |
| 7 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $163.4M | 3.93% | 1,676,624 | SH |
| 8 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $124.3M | 2.99% | 1,062,049 | SH |
| 9 | ZAI LAB LTD-ADR | ZLAB | 98887Q104 | $116.6M | 2.80% | 6,137,627 | SH |
| 10 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $112.1M | 2.70% | 6,243,812 | SH |
| 11 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $111.9M | 2.69% | 4,622,151 | SH |
| 12 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $110.2M | 2.65% | 11,020,968 | SH |
| 13 | VOR BIOPHARMA INC | VOR | 929033207 | $104.4M | 2.51% | 5,673,078 | SH |
| 14 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $103.8M | 2.49% | 3,248,980 | SH |
| 15 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $102.5M | 2.46% | 4,615,144 | SH |
| 16 | DISC MEDICINE INC | IRON | 254604101 | $98.1M | 2.36% | 1,341,862 | SH |
| 17 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $80.0M | 1.92% | 4,273,356 | SH |
| 18 | SAVARA INC | SVRA | 805111101 | $76.2M | 1.83% | 12,362,205 | SH |
| 19 | AURA BIOSCIENCES INC | AURA | 05153U107 | $67.7M | 1.63% | 9,533,333 | SH |
| 20 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $63.8M | 1.53% | 340,899 | SH |
| 21 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $58.3M | 1.40% | 2,895,304 | SH |
| 22 | KODIAK SCIENCES INC | KOD | 50015M109 | $56.3M | 1.35% | 1,445,538 | SH |
| 23 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $55.8M | 1.34% | 3,017,120 | SH |
| 24 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $47.0M | 1.13% | 1,447,310 | SH |
| 25 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $43.4M | 1.04% | 17,754,430 | SH |
| 26 | TECTONIC THERAPEUTIC INC | TECX | 878972108 | $41.4M | 1.00% | 1,204,891 | SH |
| 27 | XENCOR INC | XNCR | 98401F105 | $39.5M | 0.95% | 2,452,138 | SH |
| 28 | SURROZEN INC | SRZN | 86889P208 | $38.2M | 0.92% | 1,473,101 | SH |
| 29 | EDITAS MEDICINE INC | EDIT | 28106W103 | $36.0M | 0.87% | 11,111,111 | SH |
| 30 | MBX BIOSCIENCES INC | MBX | 55287L101 | $35.9M | 0.86% | 650,000 | SH |
| 31 | PHARVARIS BV | PHVS | N69605108 | $34.9M | 0.84% | 1,008,229 | SH |
| 32 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $33.3M | 0.80% | 3,033,560 | SH |
| 33 | INFLARX N V | IFRX | N44821101 | $32.5M | 0.78% | 14,500,000 | SH |
| 34 | ALTIMMUNE INC | ALT | 02155H200 | $30.4M | 0.73% | 10,000,000 | SH |
| 35 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $27.5M | 0.66% | 1,789,617 | SH |
| 36 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $27.0M | 0.65% | 7,915,567 | SH |
| 37 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $26.7M | 0.64% | 2,053,233 | SH |
| 38 | BIOHAVEN LTD | BHVN | G1110E107 | $26.5M | 0.64% | 1,779,952 | SH |
| 39 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $22.5M | 0.54% | 696,560 | SH |
| 40 | ALECTOR INC | ALEC | 014442107 | $20.1M | 0.48% | 10,000,000 | SH |
| 41 | FORTE BIOSCIENCES INC | FBRX | 34962G208 | $19.6M | 0.47% | 920,000 | SH |
| 42 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $18.8M | 0.45% | 203,327 | SH |
| 43 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $16.2M | 0.39% | 1,647,752 | SH |
| 44 | ADC THERAPEUTICS SA | ADCT | H0036K147 | $12.2M | 0.29% | 11,390,175 | SH |
| 45 | ALX ONCOLOGY HOLDINGS INC | ALXO | 00166B105 | $11.7M | 0.28% | 5,655,487 | SH |
| 46 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $7.8M | 0.19% | 1,060,230 | SH |
| 47 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $7.4M | 0.18% | 406,786 | SH |
| 48 | ARVINAS HOLDING CO LLC | ARVN | 04335A105 | $5.9M | 0.14% | 707,098 | SH |
| 49 | KORRO BIO INC | KRRO | 500946108 | $5.5M | 0.13% | 416,301 | SH |
| 50 | RESEARCH ALLIANCE CORP CL A | RACC | G75226103 | $5.3M | 0.13% | 500,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $4.16B | 54 | 0001214659-26-010290 |
| 2026-03-31 | 2026-05-15 | $3.50B | 49 | 0001214659-26-006367 |
| 2025-12-31 | 2026-02-17 | $3.02B | 43 | 0001214659-26-001871 |
| 2025-09-30 | 2025-11-17 | $2.03B | 40 | 0001214659-25-016751 |
PALO ALTO, CA 94301